New hope for Hard-to-Treat gut cancers: first human trial launches

NCT ID NCT07263594

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 23 times

Summary

This study tests a new drug called DB-1324 in people with advanced stomach, bowel, or other gastrointestinal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 127 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AUS01-0
RECRUITING

Nedlands, Western Australia, 6009, Australia
AUS02-0
RECRUITING

Randwick, New South Wales, 2031, Australia
AUS03-0
RECRUITING

South Brisbane, Queensland, 4101, Australia
CHN01-0
RECRUITING

Beijing, 100142, China
CHN04-0
RECRUITING

Beijing, 102206, China
USA01-0
RECRUITING

Huntersville, North Carolina, 28078, United States
USA02-0
RECRUITING

Grand Rapids, Michigan, 49546, United States
USA03-0
RECRUITING

Cincinnati, Ohio, 45219, United States
USA05-0
RECRUITING

Port Saint Lucie, Florida, 34952, United States

Conditions

Explore the condition pages connected to this study.

GASTROINTESTINAL CANCER